TrialNature medicine2023

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.

Si-Yang Maggie Liu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.